Open Accessibility Menu
Hide

Breast Clinical Trials

Study Name: ASCENT-05

  • Cancer Stage: I-III
  • Key Inclusion: TNBC; Residual Disease
  • Description: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/​AFT-65 OptimICE-RD/​NSABP B-63).
  • Study Number: GS-US-595-6184
  • NCT#: NCT05633654

Study Name: OFSET

  • Cancer Stage: I-II
  • Key Inclusion: Oncotype 16-26
  • Description: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/​HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
  • Study Number: NRG-BR009
  • NCT#: NCT05879926

Study Name: CC011

  • Cancer Stage: I-III
  • Key Inclusion: Survivor
  • Description: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors.
  • Study Number: NRG-CC011
  • NCT#: NCT05896189

Study Name: OptimICE-PCR

  • Cancer Stage: I-II
  • Key Inclusion: CR TNBC Adjuvant
  • Description: Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab.
  • Study Number: A012103
  • NCT#: NCT05812807

Study Name: Scarlet

  • Cancer Stage: N/A
  • Key Inclusion: N/A
  • Description: Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
  • Study Number: S2212
  • NCT#: NCT05929768

Study Name: S2206

  • Cancer Stage: II-III
  • Key Inclusion: MammaPrint Index Score, HER2+
  • Description: Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
  • Study Number: S2206
  • NCT#: NCT06058377

Study Name: Short-STOP

  • Cancer Stage: II-III
  • Key Inclusion: HER2+
  • Description: ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
  • Study Number: A012303
  • NCT#: NCT06876714

Study Name: EXActDNA-003

  • Cancer Stage: N/A
  • Key Inclusion: Tumor size ≥ 2.1 cm in greatest diameter; Early Stage
  • Description: Participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis.
  • Study Number: 2023-05
  • NCT#: NCT06401421

Study Name: PIKALO-2

  • Cancer Stage: Advanced
  • Key Inclusion: PIK3CA mutation
  • Description: J6M-MC-JSGD : A Phase 3, Randomized, Double-blind, Placebo-controlled Study of LY4064809 Combined with a CDK4/6 inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation who received no prior treatment for Advanced Breast Cancer (PIKALO-2)
  • Study Number: J6M-MC-JSGD
  • NCT#: NCT07174336

For more information, call 240-566-4100

All Locations